|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-03
|
$418,127
|
$418,127
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
A microRNA mediating vascular directed fibrinolysis and tumor progression
|
5F31CA213793-03
|
$33,794
|
$33,794
|
MCCANN, JAMES
|
UNIVERSITY OF VIRGINIA
|
|
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
|
5R01CA175318-04
|
$354,563
|
$354,563
|
HATEFI, ARASH
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
A New Ovarian Cancer Mouse Model Based on Nanoparticle Gene Delivery
|
5R03CA216127-02
|
$83,750
|
$83,750
|
YANG, YANG
|
YALE UNIVERSITY
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
|
5R01CA217179-02
|
$559,312
|
$559,312
|
MARKERT, JAMES
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
$273,437
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
|
1R01CA226537-01
|
$673,092
|
$336,546
|
PASQUALINI, RENATA
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Administrative Supplement: Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer
|
3R01CA195503-04S1
|
$55,777
|
$55,777
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,860,145
|
$744,058
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$546,995
|
$164,099
|
Fry, Terry
|
CCR (NCI)
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$19,101
|
$19,101
|
Kochenderfer, James
|
CCR (NCI)
|
|
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice
|
1R01CA222804-01A1
|
$414,488
|
$414,488
|
GLORIOSO, JOSEPH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Biology and Transplantation of the Hematopoietic Stem Cell
|
5P01CA065493-24
|
$1,914,832
|
$421,263
|
WAGNER, JOHN
|
UNIVERSITY OF MINNESOTA
|
|
Biomaterial approaches to attenuate macrophage recognition of self-signals from cancer cells
|
1F32CA228285-01
|
$58,654
|
$29,327
|
DOOLING, LAWRENCE
|
UNIVERSITY OF PENNSYLVANIA
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
5R01CA183827-04
|
$322,194
|
$322,194
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Building on the success of the adoptive immunotherapy of cancer
|
ZIA BC 010763
|
$3,493,116
|
$873,279
|
Restifo, Nicholas
|
CCR (NCI)
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-18
|
$672,442
|
$221,906
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cell Production Core Facility
|
ZIC BC 011569
|
$897,301
|
$448,651
|
Somerville, Robert
|
CCR (NCI)
|
|
Center for Cell-based Therapy - Cures
|
ZIA BC 011855
|
$1,339,057
|
$1,339,057
|
Restifo, Nicholas
|
CCR (NCI)
|
|
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
|
1K01CA234324-01
|
$153,850
|
$76,925
|
NAGALO, BOLNI
|
MAYO CLINIC ARIZONA
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$584,022
|
$584,022
|
Beyer, Rachel
|
CCR (NCI)
|
|
Clinical Scholars Biomedical Research Training Program
|
5T32CA009512-30
|
$394,664
|
$78,933
|
CHI, PING
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
2P01CA013106-46A1
|
$4,537,433
|
$635,241
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Colorectal Cancer: Characterization of a new Cre-LoxP Model
|
5R03CA216160-02
|
$61,021
|
$30,511
|
KHARE, SHARAD
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
|
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
|
5R01CA194064-04
|
$283,650
|
$141,825
|
MING, XIN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
5R01CA151898-08
|
$392,969
|
$196,485
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
Developing a system for PDX in vivo genetic manipulation and selection
|
1R03CA223622-01
|
$75,000
|
$37,500
|
PUGACHEVA, ELENA
|
WEST VIRGINIA UNIVERSITY
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
$98,601
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Development of fully-human anti-CD30 chimeric antigen receptors
|
ZIA BC 011660
|
$95,505
|
$95,505
|
Kochenderfer, James
|
CCR (NCI)
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DICER1 and the Pleuropulmonary Blastoma Family Cancer Syndrome
|
5R01CA143167-08
|
$407,577
|
$407,577
|
HILL, DANA
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
5R01CA196604-04
|
$354,563
|
$177,282
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
|
3R01CA196947-03S1
|
$56,995
|
$56,995
|
FIGUEIREDO, MARXA
|
PURDUE UNIVERSITY
|
|
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
|
5R01CA196947-03
|
$349,968
|
$349,968
|
FIGUEIREDO, MARXA
|
PURDUE UNIVERSITY
|
|
DNA-specific pattern recognition receptor activation following DNA electroporation
|
5R01CA196796-03
|
$316,169
|
$158,085
|
HELLER, LOREE
|
OLD DOMINION UNIVERSITY
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-05
|
$2,300,000
|
$92,000
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Efficient Delivery of Plasmid DNA to Achieve Appropriate Transgene Expression
|
5R01CA186730-04
|
$359,454
|
$359,454
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
Engineering Viruses for Cancer Therapy
|
5R03CA216179-02
|
$68,598
|
$68,598
|
PENG, CHING-AN
|
UNIVERSITY OF IDAHO
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
3R01CA181598-05S1
|
$100,813
|
$50,407
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
5R01CA181598-05
|
$318,513
|
$159,257
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing miRNA Therapeutics through Combinatorial Targeting and Vehicle Free Delivery
|
5R01CA205420-02
|
$349,332
|
$174,666
|
KASINSKI, ANDREA
|
PURDUE UNIVERSITY
|
|
Enhancing viral oncolysis with vasculostatin gene delivery
|
5R01CA150153-09
|
$382,987
|
$382,987
|
KAUR, BALVEEN
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
Exploiting the Context-Dependence of Notch to Develop Safer T-ALL therapy
|
1F30CA228228-01
|
$36,023
|
$18,012
|
GORMLEY, ANNA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Exploring the therapeutic potential and pathogenic contribution of MTAP deletion in Glioblastoma
|
5F30CA206336-02
|
$49,524
|
$49,524
|
HANSEN, LANDON
|
DUKE UNIVERSITY
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
5P01CA069246-21
|
$1,316,832
|
$579,406
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Gene therapy of cancer
|
ZIA BC 010985
|
$1,860,145
|
$744,058
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
|
5R01CA207407-02
|
$371,925
|
$371,925
|
STEPHAN, MATTHIAS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$584,807
|
$116,961
|
Gottesman, Michael
|
CCR (NCI)
|
Total relevant funding to Gene Therapy for this search: $35,380,030
|